{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T12:10:38Z","timestamp":1780920638218,"version":"3.54.1"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":67,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101173","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T16:17:43Z","timestamp":1773159463000},"page":"101173","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Optimizing mercaptopurine therapy in indian pediatric ALL: The role of TPMT and NUDT15 genetic polymorphisms"],"prefix":"10.1016","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-5690-971X","authenticated-orcid":false,"given":"Jayalakshmi","family":"Venugopal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalini","family":"Sivadasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajasekaran","family":"Aiyalu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ctarc.2026.101173_bib0001","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.hoc.2009.04.009","article-title":"Acute lymphoblastic leukemia","volume":"23","author":"Onciu","year":"2009","journal-title":"Hematol. Oncol. Clin. North Am."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101173_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2022.03.017","article-title":"Allogeneic hematopoietic stem cell transplantation for adult Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia in second complete remission","volume":"28","author":"Kaito","year":"2022","journal-title":"TransPlant Cell Ther."},{"issue":"9","key":"10.1016\/j.ctarc.2026.101173_bib0003","doi-asserted-by":"crossref","DOI":"10.4155\/cli.13.71","article-title":"Considerations in the design of clinical trials for pediatric acute lymphoblastic leukemia","volume":"3","author":"Devidas","year":"2013","journal-title":"Clin Invest"},{"issue":"18","key":"10.1016\/j.ctarc.2026.101173_bib0004","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000020082","article-title":"Clinical efficacy and safety of 6-thioguanine in the treatment of childhood acute lymphoblastic leukemia: a protocol for systematic review and meta-analysis","volume":"99","author":"Chen","year":"2020","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101173_bib0005","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1002\/cpt.2095","article-title":"Effects of NT5C2 germline variants on 6-mecaptopurine metabolism in children with acute lymphoblastic leukemia","volume":"109","author":"Jiang","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101173_bib0006","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00228-011-1133-1","article-title":"Epistatic interactions between thiopurine methyltransferase (TPMT) and inosine triphosphate pyrophosphatase (ITPA) variations determine 6-mercaptopurine toxicity in Indian children with acute lymphoblastic leukemia","volume":"68","author":"Dorababu","year":"2012","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ctarc.2026.101173_bib0007","first-page":"1","article-title":"Childhood acute lymphoblastic leukemia mercaptopurine intolerance is associated with NUDT15 variants","author":"Wang","year":"2020","journal-title":"Pediatr. Res."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101173_bib0008","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/ajh.25485","article-title":"Optimizing thiopurine dosing based on TPMT and NUDT15 genotypes: it takes two to tango","volume":"94","author":"Koutsilieri","year":"2019","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ctarc.2026.101173_bib0009","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1136\/gutjnl-2023-329679","article-title":"Drug rediscovery in gastroenterology: from off-label to on-label use of thioguanine in inflammatory bowel disease","volume":"72","author":"de Boer","year":"2023","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101173_bib0010","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/00498254.2019.1688424","article-title":"Reducing risk in thiopurine therapy","volume":"50","author":"Marinaki","year":"2020","journal-title":"Xenobiotica"},{"key":"10.1016\/j.ctarc.2026.101173_bib0011","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5217\/ir.2020.00155","article-title":"Use of thiopurines in inflammatory bowel disease: an update","volume":"20","author":"Singh","year":"2022","journal-title":"Intest. Res."},{"key":"10.1016\/j.ctarc.2026.101173_bib0012","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1001\/jama.2021.2918","article-title":"Management of Crohn disease","volume":"325","author":"Bayoumy","year":"2021","journal-title":"JAMa"},{"key":"10.1016\/j.ctarc.2026.101173_bib0013","series-title":"StatPearls [Internet]","article-title":"Mercaptopurine. [Updated 2023 May 22]","author":"Sharma","year":"2024"},{"issue":"4\u20136","key":"10.1016\/j.ctarc.2026.101173_bib0014","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1080\/15257770.2014.904519","article-title":"Assessment of mercaptopurine (6MP) metabolites and 6MP metabolic key-enzymes in childhood acute lymphoblastic leukemia","volume":"33","author":"Wojtuszkiewicz","year":"2014","journal-title":"Nucleosides. Nucleotides. Nucleic. Acids."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101173_bib0015","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1002\/cpt.2894","article-title":"Thiopurine methyltransferase intermediate metabolizer status and Thiopurine-associated toxicity during maintenance therapy in childhood acute lymphoblastic leukemia","volume":"113","author":"Schwarz","year":"2023","journal-title":"Clin. Pharmacol. Ther."},{"issue":"22","key":"10.1016\/j.ctarc.2026.101173_bib0016","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1182\/blood-2017-11-815506","article-title":"Preclinical evaluation of NUDT15-guided thiopurine therapy and its effects on toxicity and antileukemic efficacy","volume":"131","author":"Nishii","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101173_bib0017","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1186\/1471-2407-14-299","article-title":"Prevalence of TPMT and ITPA gene polymorphisms and effect on mercaptopurine dosage in Chilean children with acute lymphoblastic leukemia","volume":"14","author":"Farfan","year":"2014","journal-title":"BMC. Cancer"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101173_bib0018","doi-asserted-by":"crossref","first-page":"823","DOI":"10.4143\/crt.2017.351","article-title":"APEX1 Polymorphism and mercaptopurine-related early onset neutropenia in pediatric acute lymphoblastic leukemia","volume":"50","author":"Kim","year":"2018","journal-title":"Cancer Res.Treat"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101173_bib0019","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2174\/1871525715666170529091921","article-title":"Thiopurine S-methyltransferase as a pharmacogenetic biomarker: significance of testing and review of major methods","volume":"15","author":"Asadov","year":"2017","journal-title":"Cardiovasc. Hematol. Agents Med. Chem."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101173_bib0020","doi-asserted-by":"crossref","DOI":"10.1097\/FTD.0000000000000548","article-title":"Distribution of genetic polymorphisms of genes implicated in thiopurine drugs metabolism","volume":"40","author":"Chadli","year":"2018","journal-title":"Ther. Drug Monit."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101173_bib0021","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/tpj.2015.83","article-title":"Pharmacogenetics and induction\/consolidation therapy toxicities in acute lymphoblastic leukemia patients treated with AIEOP-BFM ALL 2000 protocol","volume":"17","author":"Franca","year":"2017","journal-title":"Pharmacogenom. J."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101173_bib0022","doi-asserted-by":"crossref","DOI":"10.1097\/01.fpc.0000114745.08559.db","article-title":"Comprehensive analysis of thiopurine S- methyltransferase phenotype\u2013genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants","volume":"14","author":"Schaeffeler","year":"2004","journal-title":"Pharmacogenetics"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101173_bib0023","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/bcp.12226","article-title":"Implementation of TPMT testing","volume":"77","author":"Lennard","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"10","key":"10.1016\/j.ctarc.2026.101173_bib0024","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1080\/17425255.2021.1974398","article-title":"Understanding thiopurine methyltransferase polymorphisms for the targeted treatment of hematologic malignancies","volume":"17","author":"Franca","year":"2021","journal-title":"Expert. Opin. Drug Metab. Toxicol."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101173_bib0025","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/pbc.24928","article-title":"The association between fasting hypoglycemia and methylated mercaptopurine metabolites in children with acute lymphoblastic leukemia","volume":"61","author":"Melachuri","year":"2014","journal-title":"Pediatr. Blood Cancer"},{"issue":"2","key":"10.1016\/j.ctarc.2026.101173_bib0026","first-page":"256","article-title":"Pharmacogenetics of thiopurines","volume":"2","author":"Franca","year":"2019","journal-title":"Cancer Drug Resist."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101173_bib0027","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.bbrc.2013.06.067","article-title":"Differential role of thiopurine methyltransferase in the cytotoxic 611 effects of 6-mercaptopurine and 6-thioguanine on human leukemia cells","volume":"437","author":"Karim","year":"2013","journal-title":"Biochem. Biophys. Res. 612 Commun."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101173_bib0028","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1365-2125.2010.03867.x","article-title":"Determinants of mercaptopurine toxicity in paediatric acute lymphoblastic leukemia maintenance therapy","volume":"71","author":"Adam de Beaumais","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101173_bib0029","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/cpt.1304","article-title":"Clinical Pharmacogenetics Implementation Consortium Guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update","volume":"105","author":"Relling","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ctarc.2026.101173_bib0030","doi-asserted-by":"crossref","DOI":"10.1371\/currents.RRN1236","article-title":"Thiopurine methyltransferase (TPMT) genotyping to predict myelosuppression risk","volume":"3","author":"Nguyen","year":"2011","journal-title":"PLoS. Curr."},{"key":"10.1016\/j.ctarc.2026.101173_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.100568","article-title":"Crystal structures of NUDT15 variants enabled by a potent inhibitor reveal the structural basis for thiopurine sensitivity","volume":"296","author":"Rehling","year":"2021","journal-title":"J. Biol. Chem."},{"issue":"10","key":"10.1016\/j.ctarc.2026.101173_bib0032","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1182\/blood-2017-05-782383","article-title":"Novel variants in NUDT15 and thiopurine intolerance in children with acute lymphoblastic leukemia from diverse ancestry","volume":"130","author":"Moriyama","year":"2017","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.ctarc.2026.101173_bib0033","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1038\/s41375-018-0190-1","article-title":"Diplotype analysis of NUDT15 variants and 6-mercaptopurine sensitivity in pediatric lymphoid neoplasms","volume":"32","author":"Tsujimoto","year":"2018","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101173_bib0034","doi-asserted-by":"crossref","first-page":"872","DOI":"10.4143\/crt.2017.283","article-title":"NUDT15 Variants cause hematopoietic toxicity with low 6-TGN levels in children with acute lymphoblastic leukemia","volume":"50","author":"Yi","year":"2018","journal-title":"Cancer Res. Treat."},{"key":"10.1016\/j.ctarc.2026.101173_bib0035","unstructured":"MERCAPTOPURINE tablet [package insert]. West Virginia, US: MylanPharmaceuticals; 2020. Available from: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=15904472-4c32-4224-95d3-eb131a7ff9c8."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101173_bib0036","first-page":"39","article-title":"Thiopurine S-methyltransferase (TPMT) mutation prevalence and myelosuppression frequency in North Indian patients with autoimmune disorders","volume":"66","author":"Ambar","year":"2018","journal-title":"J. Assoc. Physicians India"},{"issue":"5","key":"10.1016\/j.ctarc.2026.101173_bib0037","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1002\/cpt.1268","article-title":"Pharmacogene variation Consortium gene introduction: NUDT15","volume":"105","author":"Yang","year":"2019","journal-title":"Clinic. Pharmacol. Therape."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101173_bib0038","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/jnci\/djae004","article-title":"Additive effects of TPMT and NUDT15 on thiopurine toxicity in children with acute lymphoblastic leukemia across multiethnic populations","volume":"116","author":"Maillard","year":"2024","journal-title":"J. Natl. Cancer Inst."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101173_bib0039","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1038\/s41375-022-01591-4","article-title":"Maintenance therapy for acute lymphoblastic leukemia: basic science and clinical translations","volume":"36","author":"Toksvang","year":"2022","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.ctarc.2026.101173_bib0040","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/00043426-200206000-00006","article-title":"Thiopurine methyltransferase polymorphisms in a multiracial asian population and children with acute lymphoblastic leukemia","volume":"24","author":"Kham","year":"2002","journal-title":"J. Pediatr. Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101173_bib0041","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1007\/s12032-009-9331-8","article-title":"Frequency of TPMT alleles in Indian patients with acute lymphatic leukemia and effect on the dose of 6-mercaptopurine","volume":"27","author":"Desire","year":"2010","journal-title":"Med. Oncol."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101173_bib0042","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/jgh.13494","article-title":"Nucleoside diphosphate-linked moiety X-type motif 15 C415T variant as a predictor for thiopurine-induced toxicity in Indian patients","volume":"32","author":"Shah","year":"2017","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101173_bib0043","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1515\/dmpt-2017-0038","article-title":"Preemptive NUDT15 genotyping: redefining the management of patients with thiopurine-induced toxicity","volume":"33","author":"Shah","year":"2018","journal-title":"Drug Metab. Pers. Ther."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101173_bib0044","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00280-018-3732-3","article-title":"Prevalence of TPMT, ITPA and NUDT 15 genetic polymorphisms and their relation to 6MP toxicity in north Indian children with acute lymphoblastic leukemia","volume":"83","author":"Khera","year":"2019","journal-title":"Cancer Chemother Pharmacol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101173_bib0045","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1186\/s12876-021-01900-8","article-title":"TPMT and NUDT15 polymorphisms in thiopurine induced leucopenia in inflammatory bowel disease: a prospective study from India","volume":"21","author":"Grover","year":"2021","journal-title":"BMC. Gastroenterol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101173_bib0046","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/s43440-020-00158-3","article-title":"Pharmacogenetic determinants of thiopurines in an Indian cohort","volume":"73","author":"Naushad","year":"2021","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.ctarc.2026.101173_bib0047","article-title":"Prevalence and impact of TPMT and NUDT15 gene polymorphisms on consolidation phase chemotherapy in pediatric ALL","author":"Sampagar","year":"2025","journal-title":"Indian J. Med. Paediatric Oncol."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226000845?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226000845?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T11:42:05Z","timestamp":1780918925000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226000845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":47,"alternative-id":["S2468294226000845"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101173","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimizing mercaptopurine therapy in indian pediatric ALL: The role of TPMT and NUDT15 genetic polymorphisms","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101173","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101173"}}